2-(2-ethoxy-4-propylsulfanyl-5 methoxyphenyl)ethanaminium chloride

Abstract

The disclosure relates to 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-1-aminium chloride (2- (2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride), crystalline 2-(2-ethoxy-4- propylsulfanyl-5-methoxyphenyl)ethanaminium chloride, and specific crystalline forms thereof, including crystalline form 1 of 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride, to compositions containing the same, and to methods of treatment using them.

Description

2-(2-ETHOXY-4-PROPYLSULFANYL-5-METHOXYPHENYL)ETHANAMINIUM CHLORIDECross-Reference to Related Applications

[0001] This application claims priority to U.S. Provisional Application No. 63 / 511,260, filed on June 30, 2023; the disclosure of which is incorporated herein by reference.Technical Field

[0002] This disclosure relates to 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride or 2CT7-2EtO chloride), crystalline 2CT7-2EtO chloride, and specific crystalline forms thereof, including crystalline form 1 of 2CT7-2EtO chloride; to pharmaceutical compositions containing 2CT7-2EtO chloride or crystalline 2CT7- 2EtO chloride, including crystalline form 1 of 2CT7-2EtO chloride; and to methods of treatment / therapeutic uses of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, including crystalline form 1 of 2CT7-2EtO chloride.Background of the Invention

[0003] Obtaining specific salts or crystalline forms of an active pharmaceutical ingredient (API) is extremely useful in drug development. It permits better characterization of the drug candidate's chemical and physical properties. Crystalline forms often have better chemical and physical properties than the API in its amorphous state. Such crystalline forms may possess more favorable pharmaceutical and pharmacological properties or be easier to process. Additionally, preparing a crystalline API and solving its crystal structure provides the gold standard for chemical characterization and determining the molecular formula (and molecular weight) of the API. Accordingly, preparing a crystalline form with an accompanying crystal structure thereof prevents potential ambiguities and / or inaccuracies in the API's molecular weight. This is important because the API's molecular weight is used to calculate the concentration of compositions comprising that API. Thus, inaccuracies in molecular weight may lead to errors in the calculations pertaining to dosing, potency, toxicity, etc. in all downstream in vitro and in vivo assays that correlated the concentration of the API with a measured property. Accordingly, there remains a need to obtain and characterize crystalline forms of APIs, such as tryptamines and other psychedelic drug compounds.Summary of the Invention

[0004] This disclosure relates to 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride or 2CT7-2EtO chloride), crystalline 2CT7-2EtO chloride, and specific crystalline forms thereof. In one embodiment, this disclosure pertains to particular crystalline forms of 2CT7-2EtO chloride, including crystalline form 1 of 2CT7-2EtO chloride. In one embodiment, crystalline form 1 of 2CT7-2EtO chloride is characterized by at least one of: a monoclinic, P2i / c space group at a temperature of about 300(2) K; unit cell dimensions a = 17.660(3) A, b = 8.5544(10) A, c = 11.0406(14) A, a = 90°, = 90.701(5)°, and y = 90°; an X-ray powder diffraction (XRPD) pattern substantially similar to FIG. 3; and an X-ray powder diffraction pattern characterized by at least two peaks selected from 11.5, 13.1, and 14.4 °20 ± 0.2 °20.

[0005] The disclosure further relates to a composition comprising 2CT7-2EtO chloride, crystalline 2CT7-2EtO chloride, or specific crystalline forms thereof, such as crystalline form 1 of 2CT7-2EtO chloride, and at least one excipient.

[0006] The disclosure also provides a composition comprising 2CT7-2EtO chloride, crystalline 2CT7- 2EtO chloride, or specific crystalline forms thereof, such as crystalline form 1 of 2CT7-2EtO chloride, as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone; and at least one excipient.

[0007] The disclosure also relates to a method of preventing or treating a psychological disorder comprising the step of administering to a subject in need thereof a therapeutically effective amount of 2CT7-2EtO chloride, crystalline 2CT7-2EtO chloride, or specific crystalline forms thereof, such as crystalline form 1 of 2CT7-2EtO chloride, or a composition according to this disclosure.

[0008] The disclosure further relates to a method of preventing or treating inflammation and / or pain, preventing or treating a neurological disorder, modulating activity of a mitogen-activated protein kinase (MARK), modulating neurogenesis, or modulating neurite outgrowth comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of 2CT7- 2EtO chloride, crystalline 2CT7-2EtO chloride, or specific crystalline forms thereof, such as crystalline form 1 of 2CT7-2EtO chloride, and to administering a pharmaceutical composition or a composition according to the invention.

[0009] As used herein, the term "a subject in need thereof" refers to a person requiring a composition to treat a particular disease or condition (e.g., inflammation, pain, a psychological disorder, modulatingactivity at a receptor, etc.). In one embodiment, the "subject in need thereof" may be identified by analyzing, diagnosing, and / or determining whether the person (or subject) requires the composition for treatment of a particular disease or condition. In one embodiment, identifying a person in need of treatment comprises diagnosing a person with a medical condition, e.g., a neurological disorder, a chemical imbalance, a hereditary condition, etc. In one embodiment, identifying a person in need of treatment comprises performing a psychiatric evaluation. In one embodiment, identifying a person in need of treatment comprises performing a blood test. In one embodiment, identifying a person in need of treatment comprises determining whether a person has a compulsive disorder. In one embodiment, identifying a person in need of treatment comprises self-identifying as having a compulsive disorder.Description of the Figures

[0010] FIG. 1 shows the molecular structure of crystalline form 1 of 2-(2-ethoxy-4-propylsulfanyl-5- methoxyphenyl)ethanaminium chloride.

[0011] FIG. 2 shows the unit cell of crystalline form 1 of 2-(2-ethoxy-4-propylsulfanyl-5- methoxyphenyl)ethanaminium chloride along the c-axis.

[0012] FIG. 3 shows the simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 2- (2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride.Detailed Description

[0013] Compounds

[0014] This disclosure relates to 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride or 2CT7-2EtO chloride), crystalline 2CT7-2EtO chloride, and specific crystalline forms thereof, including crystalline form 1 of 2CT7-2EtO chloride, and to compositions containing 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride (such as crystalline form 1 of 2CT7-2EtO chloride) according to the disclosure. The therapeutic uses of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, including crystalline form 1 of 2CT7-2EtO chloride, according to the disclosure are described below as well as compositions containing it. 2CT7- 2EtO chloride or crystalline 2CT7-2EtO chloride, including crystalline form 1 of 2CT7-2EtO chloride, and some exemplary methods used to characterize it are described below.

[0015] 2CT7-2EtO chloride has the following chemical formula:

[0016] Methods of Treatment and Therapeutic Uses

[0017] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride (such as crystalline form 1 of 2CT7-2EtO chloride) according to the disclosure; and the methods and the compositions (e.g., pharmaceutical compositions) are used to regulate the activity of a neurotransmitter receptor by administering a therapeutically effective dose of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure. In one embodiment, 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, according to the disclosure, and the methods and the compositions (e.g., pharmaceutical compositions) are used to treat inflammation and / or pain by administering a therapeutically effective dose of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure.

[0018] Methods of the disclosure also relate to the administration of a therapeutically effective amount of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, to prevent or treat a disease or condition, such as those discussed below for a subject in need of treatment. 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7- 2EtO chloride, may be administered neat or as a composition comprising 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, as discussed below.

[0019] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to prevent and / or treat a psychological disorder. The disclosure provides a method for preventing and / or treating a psychological disorder by administering to a subject in need thereof a therapeutically effective amount of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure, including the exemplary embodiments discussed herein. The psychological disorder may be chosen from: depression; psychotic disorder; schizophrenia; schizophreniform disorder (acute schizophrenic episode); schizoaffective disorder; bipolar I disorder (mania, manic disorder, manic-depressive psychosis); bipolar II disorder; major depressive disorder; major depressive disorder with psychotic feature (psychotic depression);delusional disorders (paranoia); shared psychotic disorder (shared paranoia disorder); brief psychotic disorder (other and unspecified reactive psychosis); psychotic disorder not otherwise specified (unspecified psychosis); paranoid personality disorder; schizoid personality disorder; schizotypal personality disorder; anxiety disorder; social anxiety disorder; substance-induced anxiety disorder; selective mutism; panic disorder; panic attacks; agoraphobia; attention deficit syndrome; post-traumatic stress disorder (PTSD); premenstrual dysphoric disorder (PMDD); and premenstrual syndrome (PMS).

[0020] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to prevent and / or treat a brain disorder. The disclosure provides a method for preventing and / or treating a brain disorder (e.g., Huntington's disease, Alzheimer's disease, dementia, and Parkinson's disease) by administering to a subject in need thereof a therapeutically effective amount of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride.

[0021] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to prevent and / or treat developmental disorders, delirium, dementia, amnestic disorders and other cognitive disorders, psychiatric disorders due to a somatic condition, drug-related disorders, schizophrenia and other psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, eating disorders, sleep disorders, impulse control disorders, adjustment disorders, or personality disorders. The disclosure provides a method for preventing and / or treating these disorders by administering to a subject in need thereof a therapeutically effective amount of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, including the exemplary embodiments discussed above.

[0022] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to prevent and / or treat inflammation and / or pain, such as for example inflammation and / or pain associated with inflammatory skeletal or muscular diseases or conditions. The disclosure provides a method for preventing and / or treating an inflammation and / or pain by administering to a subject in need thereof a therapeutically effective amount of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure, including the exemplary embodiments discussed herein. Generally speaking, treatable "pain" includes nociceptive, neuropathic, and mix-type. A method of the disclosure may reduce or alleviate the symptoms associated with inflammation, including but not limited to treating localized manifestation of inflammation characterized by acute or chronic swelling, pain, redness, increased temperature, or loss of function in some cases. A method of the disclosure may reduce or alleviate the symptoms of painregardless of the cause of the pain, including but not limited to reducing pain of varying severity, i.e., mild, moderate and severe pain, acute pain and chronic pain. A method of the disclosure is effective in treating joint pain, muscle pain, tendon pain, burn pain, and pain caused by inflammation such as rheumatoid arthritis. Skeletal or muscular diseases or conditions which may be treated include but are not limited to musculoskeletal sprains, musculoskeletal strains, tendinopathy, peripheral radiculopathy, osteoarthritis, joint degenerative disease, polymyalgia rheumatica, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, costochondritis, tendonitis, bursitis, such as the common lateral epicondylitis (tennis elbow), medial epicondylitis (pitchers elbow) and trochanteric bursitis, temporomandibular joint syndrome, and fibromyalgia.

[0023] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to modulate activity of a mitogen-activated protein kinase (MAPK), comprising administering a composition of the invention. MAPKs provide a wide-ranging signaling cascade that allows cells to quickly respond to biotic and abiotic stimuli. Exemplary MAPKs include, but are not limited to, Tropomyosin Receptor Kinase A (TrkA), P38-alpha, and c-Jun N-Terminal Kinase 3 (JNK3). TrkA is a high affinity catalytic receptor of nerve growth factor (NGF) protein. TrkA regulates NGF response, influencing neuronal differentiation and outgrowth as well as programmed cell death. p38-alpha is involved with the regulation of pro-inflammatory cytokines, including TNF-a. In the central nervous system, p38-alpha regulates neuronal death and neurite degeneration, and it is a common target of Alzheimer's disease therapies. JNK3 is a neuronal-specific protein isoform of the JNKs. It is involved with the regulation of apoptosis. JNK3 also plays a role in modulating the response of cytokines, growth factors, and oxidative stress.

[0024] As used herein, the term "modulating activity of a mitogen-activated protein kinase" refers to changing, manipulating, and / or adjusting the activity of a mitogen-activated protein kinase. In one embodiment, modulating the activity of a MAPK can influence neural health, neurogenesis, neural growth and differentiation, and neurodegenerative diseases.

[0025] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to modulate neurogenesis, comprising administering a composition of the invention. As used herein, the term "modulating neurogenesis" refers to changing, manipulating, and / or adjusting the growth and development of neural tissue. In one embodiment, neurogenesis comprises adult neurogenesis, in which new neural stem cells are generated from neural stem cells in an adult animal. In one embodiment, modulating neurogenesis comprises increasing and / or enhancing the rate at which new neural tissue is developed.

[0026] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to modulate neurite outgrowth, comprising administering a composition of the invention. As used herein, the term "modulating neurite outgrowth" refers to changing, manipulating, and / or adjusting the growth and development of neural projections, or "neurites." In one embodiment, neurogenesis comprises modulating the growth of new neurites, the number of neurites per neuron, and / or neurite length. In one embodiment, modulating neurite outgrowth comprises increasing and / or enhancing the rate and / or length at which neurites develop.

[0027] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to prevent and / or treat sexual health disorders including, but not limited to, hypoactive sexual desire disorder, hyperactive sexual desire disorder, orgasmic disorder, arousal disorder, vaginismus, and dyspareunia. In some embodiments, the disorder is a male sexual dysfunction disorder. In some embodiments, the disorder is a female sexual dysfunction disorder.

[0028] 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used to prevent and / or treat women's health disorders including, but not limited to, menstrual cramping, dysmenorrhea, post-hysterectomy pain, vaginal or vulvar vestibule mucosa disorder, menopausal-related disorders, vaginal atrophy, or vulvar vestibulitis.

[0029] Compositions

[0030] The disclosure also relates to compositions comprising an effective amount of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, and an excipient (e.g., a pharmaceutically-acceptable excipient). In another embodiment, the disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, and a pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier). As discussed above, 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be, for example, therapeutically useful to prevent and / or treat the psychological disorders, brain disorders, pain, and inflammation as well as the other disorders described herein.

[0031] A composition or a pharmaceutical composition of the disclosure may be in any form which contains 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride. The composition may be, for example, a tablet, capsule, liquid suspension, injectable, topical, or transdermal. The compositions generally contain, for example, about 1% to about 99% by weight of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride,of the disclosure and, for example, 99% to 1% by weight of at least one suitable pharmaceutically acceptable excipient. In one embodiment, the composition may be between about 5% and about 75% by weight of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7- 2EtO chloride, of the disclosure, with the rest being at least one suitable pharmaceutically acceptable excipient or at least one other adjuvant, as discussed below.

[0032] Published US applications US 2018 / 0221396 Al and US 2019 / 0142851 Al disclose compositions comprising a combination of a first purified psilocybin derivative with a second purified psilocybin derivative, with one or two purified cannabinoids or with a purified terpene. Various ratios of these components in the composition are also disclosed. The disclosures of US 2018 / 0221396 Al and US 2019 / 0142851 Al are incorporated herein by reference. According to this disclosure, 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used as the "first purified psilocybin derivative" in the compositions described in US 2018 / 0221396 Al and US 2019 / 0142851 Al. Accordingly, this disclosure provides a composition comprising: a first component comprising 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure; at least one second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, and (d) a purified terpene; and at least one pharmaceutically-acceptable excipient or at least one other adjuvant. Such a composition may be a pharmaceutical composition wherein the components are present individually in therapeutically effective amounts or by combination in a therapeutically effective amount to treat a disease, disorder, or condition as described herein.

[0033] When used in such compositions as a first component comprising 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure with a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, and (d) a purified terpene, the compositions represent particular embodiments of the invention. Compositions having as a first component 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure with a second component selected from at least one of (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone represent additional particular embodiments of the invention represented by the compositions having 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, according to the disclosure. In some embodiments, the first and second components can be administered at the same time (e.g., together in the same composition), or at separate times over the course of treating a patientin need thereof. Such a composition may be a pharmaceutical composition wherein the components are present individually in therapeutically effective amounts or by combination in a therapeutically effective amount to treat a disease, disorder, or condition as described herein.

[0034] Within the context of this disclosure, the term "purified" means separated from other materials, such as plant or fungal material, e.g., protein, chitin, cellulose, or water. In one embodiment, the term "purified" refers to a compound substantially free of other materials. In one embodiment, the term "purified" refers to a compound that is substantially free from a second tryptamine compound. In one embodiment, the term "purified" refers to a compound substantially free from histidine. In one embodiment, the term "purified" refers to a compound substantially free from a biological material, such as mold, fungus, plant matter, or bacteria. In one embodiment, the term "purified" refers to a compound substantially free from a paralytic.

[0035] In one embodiment, the term "purified" refers to a compound which has been separated from other compounds that are typically co-extracted when the purified compound is extracted from a naturally occurring organism. In one embodiment, a "purified" psilocybin derivative is partially or completely isolated from other psilocybin derivatives present in a source material, such as a psil ocybin- containing mushroom. In one example, "purified" baeocystin is substantially free from psilocybin and / or psilocin. By contrast, traditional psilocybin mushroom extracts (aka crude extracts or fruit body extracts) would be expected to contain an unpredictable and varying amount of psilocybin, psilocin, baeocystin, norbaeocystin, salts thereof, or combinations thereof. Other examples of unpurified psilocybin derivatives would include mycelium containing psilocybin derivatives and / or naturally occurring fungal material such as biological material and / or structural material such as chitin. Similarly, the term "cannabis extracts" or "cannabinoid extracts" traditionally refers to whole plants (aka crude or full spectrum extracts) which have not been subjected to further purification to eliminate unwanted molecules that naturally occur in the cannabis plant. For example, a "cannabis extract comprising cannabidiol" could be expected to include cannabidiol (aka "CBD") and also varying amounts of other compounds, including cannabinoids, terpenes, and other biological material.

[0036] In one embodiment, the term "purified" refers to a compound or composition that has been crystallized.

[0037] In one embodiment, the term "purified" refers to a compound or composition that has been chromatographed, for example by gas chromatography, liquid chromatography (e.g., LC, HPLC, etc.), etc.

[0038] In one embodiment, the term "purified" refers to a compound or composition that has been distilled.

[0039] In one embodiment, the term "purified" refers to a compound or composition that has been sublimed.

[0040] In one embodiment, the term "purified" refers to a compound or composition that has been subject to two or more steps chosen from crystallization, chromatography, distillation, or sublimation.

[0041] In one embodiment, the term "purified" refers to a compound that is between 80-100% pure.

[0042] In one embodiment, the term "purified" refers to a compound that is between 90-100% pure.

[0043] In one embodiment, the term "purified" refers to a compound that is between 95-100% pure.

[0044] In one embodiment, the term "purified" refers to a compound that is between 99-100% pure.

[0045] In one embodiment, the term "purified" refers to a compound that is between 99.9-100% pure.

[0046] A serotonergic drug refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor as described in paragraphs

[0245] -

[0253] of US 2018 / 0221396 Al and

[0305] -

[0311] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments. Exemplary psilocybin derivatives include but are not limited to psilocybin itself and the psilocybin derivatives described in paragraphs

[0081] -

[0109] of US 2018 / 0221396 Al and

[0082] -

[0110] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments. Exemplary cannabinoids include but are not limited to the cannabinoids described in paragraphs

[0111] -

[0145] of US 2018 / 0221396 Al and

[0112] -

[0146] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments. Exemplary terpenes include but are not limited to the terpenes described in paragraphs

[0160] -

[0238] of US 2018 / 0221396 Al and

[0161] -

[0300] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments.

[0047] A pharmaceutical formulation of the disclosure may comprise, consist essentially of, or consist of (a) 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure and (b) at least one second active compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, a purified terpene, an adrenergic drug, a dopaminergic drug, a monoamine oxidase inhibitor, a purified erinacine, and a purified hericenone, and (c) a pharmaceutically acceptable excipient. In some embodiments, 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, and the second active compound(s) are each present in a therapeutically effective amount using purposefully engineered and unnaturally occurring molar ratios. Exemplary molar ratios of 2CT7-2EtO chloride or crystalline 2CT7- 2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure to the second active compound in a composition of the disclosure include but are not limited to from about 0.1:100 to about100:0.1, from about 1:100 to about 100:1, from about 1:50 to about 50:1, from about 1:25 to about 25:1, from about 1:20 to about 20:1, from about 1:10 to about 10:1, from about 1:5 to about 5:1, from about 1:2 to about 2:1 or may be about 1:1.

[0048] A pharmaceutical formulation of the disclosure may comprise a composition containing 2CT7- 2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form l of 2CT7-2EtO chloride, of the disclosure and a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene, each present in a therapeutically effective amount using purposefully engineered and unnaturally occurring molar ratios. Published US applications US 2018 / 0221396 Al and US 2019 / 0142851 Al disclose compositions comprising a combination of a purified psilocybin derivative with a second purified psilocybin derivative, with one or two purified cannabinoids or with a purified terpene. According to this disclosure composition containing 2CT7-2EtO chloride or crystalline 2CT7- 2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be used in place of a "purified psilocybin derivative" in the compositions described in US 2018 / 0221396 Al and US 2019 / 0142851 Al. Accordingly, the disclosure provides a pharmaceutical formulation comprising as (a) 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure and at least one second component selected from (a) a purified psilocybin derivative, (b) a purified cannabinoid, and (c) a purified terpene; and at least one pharmaceutically-acceptable excipient or at least one other adjuvant, as described herein. Such a composition may be a pharmaceutical composition wherein the components are present individually in therapeutically effective amounts or by combination in a therapeutically effective amount to treat a disease, disorder, or condition as described herein.

[0049] A serotonergic drug refers to a compound that binds to, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a serotonin receptor as described in paragraphs

[0245] -

[0253] of US 2018 / 0221396 Al and

[0305] -

[0311] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments. Some exemplary serotonergic drugs include SSRIs and SNRIs. Some examples of specific serotonergic drugs include the following molecules, including any salts, solvates, or polymorphs thereof: 6-allyl-N,N-diethyl-NL; N,N-dibutyl-T; N,N-diethyl-T; N,N-diisopropyl-T; 5-methyoxy-alpha-methyl-T; N,N- dimethyl-T; 2,alpha-dimethyl-T; alpha, N-dimethyl-T; N,N-dipropyl-T; N-ethyl-N-isopropyl-T; alpha-ethyl- T; 6-N, N-Triethyl-NL; 3,4-dihydro-7-methoxy-l-methyl-C; 7-methyoxy-l-methyl-C; N, N-dibutyl-4- hydroxy-T; N,N-diethyl-4-hydroxy-T; N,N-diisopropyl-4-hydroxy-T; N,N-dimethyl-4-hydroxy-T; N,N- dimethyl-5-hydroxy-T; N, N-dipropyl-4-hydroxy-T; N-ethyl-4-hydroxy-N-methyl-T; 4-hydroxy-N-isopropyl- N-methyl-T; 4-hydroxy-N-methyl-N-propyl-T; 4-hydroxy-N,N-tetramethylene-T; ibogaine; N,N-diethyl-L;N-butyl-N-methyl-T; N,N-diisopropyl-4,5-methylenedioxy-T; N,N-diisopropyl-5,6-methylenedioxy-T; N,N- dimethyl-4,5-methylenedioxy-T; N,N-dimethyl-5,6-methylenedioxy-T; N-isopropyl-N-methyl-5,6- methylenedioxy-T; N,N-diethyl-2-methyl-T; 2-N,N-trimethyl-T; N-acetyl-5-methoxy-T; N,N-diethyl-5- methoxy-T; N,N-diisopropyl-5-methoxy-T; 5-methoxy-N,N-dimethyl-T; N-isopropyl-4-methoxy-N-methyl- T; N-isopropyl-5-methoxy-N-methyl-T; 5,6-dimethoxy-N-isopropyl-N-methyl-T; 5-methoxy-N-methyl-T; 5-methoxy-N,N-tetramethylene-T; 6-methoxy-l-methyl-l,2,3,4-tetrahydro-C; 5-methoxy-2-N,N- trimethyl-T; N,N-dimethyl-5-methylthio-T; N-isopropyl-N-methyl-T; alpha-methyl-T; N-ethyl-T; N-methyl- T; 6-propyl-N L; N,N-tetrarnethylene-T; tryptamine; 7-methoxy-l-methyl-l,2,3,4-tetrahydro-C; and alpha, N-dimethyl-5-methoxy-T. For additional information regarding these compounds see Shulgin, A. T., & Shulgin, A. (2016). Tihkal: The Continuation. Berkeley, Calif.: Transform Press. In one embodiment, a serotonergic drug is chosen from alprazolam, amphetamine, aripiprazole, azapirone, a barbiturate, bromazepam, bupropion, buspirone, a cannabinoid, chlordiazepoxide, citalopram, clonazepam, clorazepate, dextromethorphan, diazepam, duloxetine, escitalopram, fluoxetine, flurazepam, fluvoxamine, lorazepam, lysergic acid diethylamide, lysergamide, 3,4- methylenedioxymethamphetamine, milnacipran, mirtazapine, naratriptan, paroxetine, pethidine, phenethylamine, psicaine, oxazepam, reboxetine, serenic, serotonin, sertraline, temazepam, tramadol, triazolam, a tryptamine, venlafaxine, vortioxetine, and / or derivatives thereof. In an exemplary embodiment, the serotonergic drug is 3,4-methylenedioxymethamphetamine.

[0050] Exemplary psilocybin derivatives include but are not limited to psilocybin itself and the psilocybin derivatives described in paragraphs

[0081] -

[0109] of US 2018 / 0221396 Al and

[0082] -

[0110] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments, incorporated here by reference. In one embodiment, the compositions disclosed herein comprise one or more purified psilocybin derivatives chosen from: [3-(2-dimethylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate; 4- hydroxytryptamine; 4-hydroxy-N,N-dimethyltryptamine; [3-(2-methylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate; 4-hydroxy-N-methyltryptamine; [3-(aminoethyl)-lH-indol-4-yl] dihydrogen phosphate; [3-(2-trimethylaminoethyl)-lH-indol-4-yl] dihydrogen phosphate; and 4-hydroxy-N,N,N- trimethyltryptamine.

[0051] Exemplary cannabinoids include but are not limited to the cannabinoids described in paragraphs

[0111] -

[0145] of US 2018 / 0221396 Al and

[0112] -

[0146] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments. Examples of cannabinoids within the context of this disclosure include the following molecules: cannabichromene (CBC); cannabichromenic acid (CBCA); cannabichromevarin (CBCV); cannabichromevarinic acid (CBCVA); cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiolic acid (CBDA); cannabidiorcol (CBD-C1); cannabidivarin (CBDV); cannabidivarinic acid (CBDVA); cannabielsoic acid B (CBEA-B); cannabielsoin (CBE); cannabielsoin acid A (CBEA-A); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerovarin (CBGV); cannabigerovarinic acid (CBGVA); cannabinodiol (CBND); cannabinodivarin (CBVD); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C2 (CBN-C2); cannabinol-C4 (CBN-C4); cannabinolic acid (CBNA); cannabiorcol (CBN-C1); cannabivarin (CBV); cannabitriol (CBT); cannabitriolvarin (CBTV); 10-ethoxy-9-hydroxy-delta-6a- tetrahydrocannabinol; cannabicitran (CBTC); cannabiripsol (CBR); 8,9-dihydroxy-delta-6a- tetrahydrocannabinol; delta-8-tetrahydrocannabinol (A8-THC); delta-8-tetrahydrocannabinolic acid (A8- THCA); delta-9-tetrahydrocannabinol (THC); delta-9-tetrahydrocannabinol-C4 (THC-C4); delta-9- tetrahydrocannabinolic acid A (THCA-A); delta-9-tetrahydrocannabinolic acid B (THCA-B); delta-9- tetrahydrocannabinolic acid-C4 (THCA-C4); delta-9-tetrahydrocannabiorcol (THC-C1); delta-9- tetrahydrocannabiorcolic acid (THCA-C1); delta-9-tetrahydrocannabivarin (THCV); delta-9- tetrahydrocannabivarinic acid (THCVA); 10-oxo-delta-6a-tetrahydrocannabinol (OTHC); cannabichromanon (CBCF); cannabifuran (CBF); cannabiglendol; delta-9-cis-tetrahydrocannabinol (cis- THC); trihydroxy-delta-9-tetrahydrocannabinol (triOH-THC); dehydrocannabifuran (DCBF); and 3, 4,5,6- tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-methano-2H-l-benzoxocin-5-methanol. In one embodiment, the purified cannabinoid is chosen from THC, THCA, THCV, THCVA, CBC, CBCA, CBCV, CBCVA, CBD, CBDA, CBDV, CBVD, CBDVA, CBG, CBGA, CBGV, or CBGVA.

[0052] Exemplary terpenes include but are not limited to the terpenes described in paragraphs

[0160] -

[0238] of US 2018 / 0221396 Al and

[0161] -

[0300] US 2019 / 0142851 Al as well as the disclosed exemplary embodiments. In one embodiment, a purified terpene is chosen from acetanisole, acetyl cedrene, anethole, anisole, benzaldehyde, bornyl acetate, borneol, cadinene, cafestol, caffeic acid, camphene, camphor, capsaicin, carene, carotene, carvacrol, carvone, caryophyllene, caryophyllene, caryophyllene oxide, cedrene, cedrene epoxide, cecanal, cedrol, cembrene, cinnamaldehyde, cinnamic acid, citronellal, citronellol, cymene, eicosane, elemene, estragole, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol / l,8-cineole, eudesmol, eugenol, euphol, farnesene, farnesol, fenchone, geraniol, geranyl acetate, guaia-l(10),ll-diene, guaiacol, guaiol, guaiene, gurjunene, herniarin, hexanaldehyde, hexanoic acid, humulene, ionone, ipsdienol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isoborneol, isomyrcenol, isoprene, isopulegol, isovaleric acid, lavandulol, limonene, gamma-linolenic acid, linalool, longifolene, lycopene, menthol, methyl butyrate, 3-mercapto-2-methylpentanal, beta-mercaptoethanol, mercaptoacetic acid, methyl salicylate, methylbutenol, methyl-2-methylvalerate, methyl thiobutyrate, myrcene, gamma-muurolene, nepetalactone, nerol, nerolidol, neryl acetate, nonanaldehyde, nonanoic acid, ocimene, octanal, octanoic acid, pentyl butyrate, phellandrene, phenylacetaldehyde, phenylacetic acid, phenylethanethiol, phytol, pinene, propanethiol, pristimerin, pulegone, retinol, rutin, sabinene, squalene, taxadiene, terpineol, terpine-4-ol, terpinolene, thujone, thymol, umbelliferone, undecanal, verdoxan, or vanillin. In one embodiment, a purified terpene is chosen from bornyl acetate, alpha-bisabolol, borneol, camphene, camphor, carene, caryophyllene, cedrene, cymene, elemene, eucalyptol, eudesmol, farnesene, fenchol, geraniol, guaiacol, humulene, isoborneol, limonene, linalool, menthol, myrcene, nerolidol, ocimene, phellandrene, phytol, pinene, pulegone, sabinene, terpineol, terpinolene, or valencene.

[0053] As used herein, the term "adrenergic drug" refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at an adrenergic receptor. In one embodiment, an adrenergic drug binds to an adrenergic receptor. In one embodiment, an adrenergic drug indirectly affects an adrenergic receptor, e.g., via interactions affecting the reactivity of other molecules at the adrenergic receptor. In one embodiment, an adrenergic drug is an agonist, e.g., a compound activating an adrenergic receptor. In one embodiment, an adrenergic drug is an antagonist, e.g., a compound binding but not activating an adrenergic receptor, e.g., blocking a receptor. In one embodiment, an adrenergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation. In one embodiment, an adrenergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.).

[0054] In one embodiment, an adrenergic drug is an antidepressant. In one embodiment, an adrenergic drug is a norepinephrine transporter inhibitor. In one embodiment, an adrenergic drug is a vesicular monoamine transporter inhibitor. In one embodiment, an adrenergic drug is chosen from adrenaline, agmatine, amoxapine, aptazapine, atomoxetine, bupropion, clonidine, doxepin, duloxetine, esmirtazpine, mianserin, ketanserin, mirabegron, mirtazapine, norepinephrine, phentolamine, phenylephrine, piperoxan, reserpine, ritodrine, setiptiline, tesofensine, timolol, trazodone, trimipramine, or xylazine.

[0055] As used herein, the term "dopaminergic drug" refers to a compound that binds, blocks, or otherwise influences (e.g., via an allosteric reaction) activity at a dopamine receptor. In one embodiment, a dopaminergic drug binds to a dopamine receptor. In one embodiment, a dopaminergic drug indirectly affects a dopamine receptor, e.g., via interactions affecting the reactivity of other molecules at the dopamine receptor. In one embodiment, a dopaminergic drug is an agonist, e.g., acompound activating a dopamine receptor. In one embodiment, a dopaminergic drug is an antagonist, e.g., a compound binding but not activating a dopamine receptor, e.g., blocking a receptor. In one embodiment, a dopaminergic drug is an effector molecule, e.g., a compound binding to an enzyme for allosteric regulation. In one embodiment, a dopaminergic drug acts (either directly or indirectly) at more than one type of receptor (e.g., 5HT, dopamine, adrenergic, acetylcholine, etc.).

[0056] In one embodiment, a dopaminergic drug is a dopamine transporter inhibitor. In one embodiment, a dopaminergic drug is a vesicular monoamine transporter inhibitor. In one embodiment, a dopaminergic drug is chosen from amineptine, apomorphine, benzylpiperazine, bromocriptine, cabergoline, chlorpromazine, clozapine, dihydrexidine, domperidone, dopamine, fluphenazine, haloperidol, ketamine, loxapine, methamphetamine, olanzapine, pemoline, perphenazine, pergolide, phencyclidine, phenethylamine, phenmetrazine, pimozide, piribedil, a psychostimulant, reserpine, risperidone, ropinirole, tetrabenazine, or thioridazine.

[0057] As used herein, the term "monoamine oxidase inhibitor" (MAOI) refers to a compound that blocks the actions of monoamine oxidase enzymes. In one embodiment, a MAOI inhibits the activity of one or both monoamine oxidase A and monoamine oxidase B. In one embodiment a MAOI is a reversible inhibitor of monoamine oxidase A. In one embodiment a MAOI is a drug chosen from isocarboxazid, phenelzine, or tranylcypromine. In one embodiment, a MAOI is 0-carboline, pinoline, harmane, harmine, harmaline, harmalol, tetrahydroharmine, 9-methyl-0-carboline, or 3-carboxy- tetrahydrononharman.

[0058] In one embodiment, the compositions and methods disclosed herein include one or more purified erinacine molecules. In one embodiment, the compositions and methods disclosed herein comprise purified erinacine A. In one embodiment, the compositions and methods disclosed herein comprise erinacine B. In one embodiment, the compositions and methods disclosed herein comprise erinacine C. In one embodiment, the compositions and methods disclosed herein comprise erinacine D. In one embodiment, the compositions and methods disclosed herein comprise erinacine E. In one embodiment, the compositions and methods disclosed herein comprise erinacine F. In one embodiment, the compositions and methods disclosed herein comprise erinacine G. In one embodiment, the compositions and methods disclosed herein comprise erinacine H. In one embodiment, the compositions and methods disclosed herein comprise erinacine I. In one embodiment, the compositions and methods disclosed herein comprise erinacine J. In one embodiment, the compositions and methods disclosed herein comprise erinacine K In one embodiment, the compositions and methods disclosed herein comprise erinacine P. In one embodiment, the compositions and methodsdisclosed herein comprise erinacine Q. In one embodiment, the compositions and methods disclosed herein comprise erinacine R. In one embodiment, the compositions and methods disclosed herein comprise erinacine S.

[0059] In one embodiment, the compositions and methods disclosed herein include one or more purified hericenone molecules. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone A. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone B. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone C. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone D. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone E. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone F. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone G. In one embodiment, the compositions and methods disclosed herein comprise purified hericenone H.

[0060] Exemplary compositions of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure and a second compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, a purified terpene, an adrenergic drug, a dopaminergic drug, a monoamine oxidase inhibitor, a purified erinacine, and a purified hericenone in exemplary molar ratios are shown in Table 1. 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be any one of the exemplary embodiments described above including the crystalline forms as disclosed herein.Table 1

[0061] Exemplary pharmaceutical compositions of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure and a second compound selected from a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, a purified terpene, an adrenergic drug, a dopaminergic drug, a monoamine oxidase inhibitor, a purified erinacine, and a purified hericenone and an excipient with exemplary molar ratios of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, to the second compound are shown in Table 2. 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be any one of the exemplary embodiments described above including the crystalline forms as disclosed herein.Table 2

[0062] An "effective amount" or a "therapeutically effective amount" of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure is generally in the range of about 0.1 to about 100 mg daily (oral dose), of about 0.1 to about 50 mg daily (oral dose), of about 0.25 to about 25 mg daily (oral dose), of about 0.1 to about 5 mg daily (oral dose), or of about 0.5 to about 2.5 mg daily (oral dose). The actual amount required for treatment of any particular patient may depend upon a variety of factors including, for example, the disease being treated and its severity; the specific pharmaceutical composition employed; the age, body weight, general health, sex, and diet of the patient; the mode of administration; the time of administration; the route of administration; and the rate of excretion; the duration of the treatment; any drugs used in combination or coincidental with the specific compound employed; and other such factors well known in the medical arts. These factors are discussed in Goodman and Gilman's "The Pharmacological Basis of Therapeutics," Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173 (2001), which is incorporated herein by reference. 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure and pharmaceutical compositions containing it may be used in combination with other agents that are generally administered to a patient being treated for psychological and other disorders discussed above. They may also be co-formulated with one or more of such agents in a single pharmaceutical composition.

[0063] Depending on the type of pharmaceutical composition, the pharmaceutically acceptable carrier may be chosen from any one or a combination of carriers known in the art. The choice of the pharmaceutically acceptable carrier depends upon the pharmaceutical form and the desired method of administration to be used. Exemplary carriers include those that do not substantially alter the structure or activity of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7- 2EtO chloride, of the disclosure, or produce undesirable biological effects or otherwise interact in a deleterious manner with any other component(s) of the pharmaceutical composition.

[0064] The pharmaceutical compositions of the disclosure may be prepared by methods know in the pharmaceutical formulation art, for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990), which is incorporated herein by reference. In a solid dosageform, 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure may be admixed with at least one pharmaceutically acceptable excipient such as, for example, sodium citrate or dicalcium phosphate or (a) fillers or extenders, such as, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, such as, for example, cellulose derivatives, starch, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, such as, for example, glycerol, (d) disintegrating agents, such as, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, such as, for example, paraffin, (f) absorption accelerators, such as, for example, quaternary ammonium compounds, (g) wetting agents, such as, for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like, (h) adsorbents, such as, for example, kaolin and bentonite, and (i) lubricants, such as, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. In some embodiments, the excipient is not water. In some embodiments, the excipient is not a solvent (e.g., EtOH, diethyl ether, ethyl acetate, or hydrocarbon-based solvents (e.g., hexanes). In some embodiments, the dosage form is substantially free of water and / or solvents, for example less than about 5% water by mass, less than 2% water by mass, less than 1% water by mass, less than 0.5% water by mass, or less than 0.1% water by mass.

[0065] Excipients or pharmaceutically acceptable adjuvants known in the pharmaceutical formulation art may also be used in the pharmaceutical compositions of the disclosure. These include, but are not limited to, preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms may be ensured by inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. If desired, a pharmaceutical composition of the disclosure may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, etc.

[0066] Solid dosage forms as described above may be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Non-limiting examples of embedded compositions that may be used arepolymeric substances and waxes. The active compounds may also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0067] Suspensions, in addition to the active compounds, may contain suspending agents, such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

[0068] Solid dosage forms for oral administration, which includes capsules, tablets, pills, powders, and granules, may be used. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient (also known as a pharmaceutically acceptable carrier).

[0069] Administration of 2CT7-2EtO chloride or crystalline 2CT7-2EtO chloride, such as crystalline form 1 of 2CT7-2EtO chloride, of the disclosure in pure form or in an appropriate pharmaceutical composition may be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration may be, for example, orally, buccally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, or intrasystemically, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, such as, for example, in unit dosage forms suitable for simple administration of precise dosages. One route of administration may be oral administration, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the diseasestate to be treated.Exemplary Embodiments of the Invention

[0070] El. 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride).

[0071] E2. Crystalline 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride).

[0072] E3. Crystalline form 1 of 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride).

[0073] E4. Crystalline form 1 of 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to E3, characterized by at least one of: a monoclinic crystal system at a temperature of about 300 K; a Pl- c space group at a temperature of about 300 K;unit cell dimensions a = 17.660(3) A, b = 8.5544(10) A, c = 11.0406(14) A, a = 90°, = 90.701(5)°, and y = 90°; an X-ray powder diffraction pattern substantially similar to FIG. 3; or an X-ray powder diffraction pattern characterized by at least two peaks selected from 11.5, 13.1, and 14.4 °20 ± 0.2 ’29.

[0074] E5. A composition comprising 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to El and an excipient.

[0075] E6. A composition comprising crystalline 2-(2-ethoxy-4-propylsulfanyl-5- methoxyphenyl)ethanaminium chloride according to any one of E2-E4 and an excipient.

[0076] E7. A composition comprising 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to El as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.

[0077] E8. A composition comprising crystalline 2-(2-ethoxy-4-propylsulfanyl-5- methoxyphenyl)ethanaminium chloride according to any one of E2-E4 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.

[0078] E9. A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 2-(2-ethoxy-4- propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to El.

[0079] E10. A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 2-(2- ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to any one of E2-E4.

[0080] Ell. A method of preventing or treating a psychological disorder comprising the step of:

[0081] administering to a subject in need thereof a composition according to E5 or E7.

[0082] E12. A method of preventing or treating a psychological disorder comprising the step of:

[0083] administering to a subject in need thereof a composition according to E6 or E8.

[0084] E13. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 2-(2-ethoxy-4- propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to El.

[0085] E14. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 2-(2- ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to any one of E2-E4.

[0086] E15. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a composition according to E5 or E7.

[0087] E16. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a composition according to E6 or E8.Examples

[0088] The preparation and characterization of crystalline form 1 of 2-[2-ethoxy-5-methoxy-4- (propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy-4-propylsulfanyl-5- methoxyphenyl)ethanarninium chloride or 2CT7-2EtO chloride) is described below.

[0089] Single Crystal X-Ray Diffraction (SCXRD) Characterization: Data were collected on a Bruker D8 Venture CMOS Diffractometer equipped with an Oxford Cryosystems Cryostream cooling device and using Mo Ka radiation. Structures were solved using the Bruker SHELXTL program and refined with the SHELXTL program as part of the Bruker SHELXTL suite, or 0LEX2 software. Unless otherwise stated, hydrogen atoms attached to carbon were placed geometrically and allowed to refine with a riding isotropic displacement parameter. Hydrogen atoms attached to a heteroatom were located in a difference Fourier synthesis and were allowed to refine freely with an isotropic displacement parameter.

[0090] Preparation and Characterization of Crystalline form 1 of 2-(2-ethoxy-4-propylsulfanyl-5- methoxyphenyl)ethanaminium chloride

[0091] Synthesis

[0092] Synthetic route for the preparation of 2CT7-2EtO chloride: (i) 100% H2SO4 / ice, 33% NaOH; (ii) (CH3O)2SO2, 33% NaOH; (iii) POCI3; (iv) Zn, 96% H2SO4 / ice; reflux; (v) Prl, KOH / EtOH; (vi) POCI3 / / V- methylformanilide; (vii) NO2CH3, NH4CO2CH3; (viii) AIH3 / THF; (xi) IPA / HCI.

[0093] Preparation of 5-ethoxy-2-methoxybenzenesulfonic acid.

[0094] Step i: 20 g of 4-ethoxyphenol (1) and 12.9 mL 100% sulfuric acid were mixed at room temperature and placed in a 30 °C water bath and stirred. The temperature was raised at the rate of not more than 1 °C / min. with constant stirring until a bath temperature of 80 °C was reached. The mixture was cooled, then poured over 70 g crushed ice, washing the flask out with 5-10 mL H?O. The mixture was stirred and 33% NaOH was slowly added until slightly basic pH. The mixture turned to a cottage cheese-like consistency. 50 mL H2O and 10 mL more of the 33% NaOH solution was added. The final temperature was 20 °C and the volume was about 180 mL.

[0095] Step ii: The mixture was transferred to a 500 mL Erlenmeyer flask and the beaker was washed out with 15 mL H20. 10 mL 33% NaOH and 10 mL dimethyl sulfate were added with swirling, then after a few minutes, another 10 mL dimethyl sulfate was added. The mixture was warmed to 60-65 °C with swirling to dissolve lumps and speed the reaction. The pH was kept above 10; if it dropped below, 10 mL 33% NaOH solution was added. Another 10 mL dimethyl sulfate was added with continued warming and swirling for a few minutes, then 10 mL more dimethyl sulfate was added, for a total of 40 mL. The mixture was heated on a steam bath for one hour.

[0096] Preparation of 5-ethoxy-2-methoxybenzenesulfonyl chloride (2).

[0097] Step iii: The solution from the previous step was evaporated to dryness, then the flask was heated in an oil bath set at 125-130 °C or an air bath at 150-160 °C, with an occasional brief air sweep. When fumes appeared in the flask during the air sweep, heating was stopped and the flask was cooled. 75 mL POCI3 was added to the foamy crust in the flask. A reflux condenser was added and the reaction was heated in boiling water bath; HCI gas was evolved. After about 20 min, most of the crust was broken up with a thin, flat, stainless-steel tool. The reaction was swirled occasionally as heating continued. After about 1.5 hr., the entire mass set up to a semi-solid. The reaction was cooled, semi-hard solids were broken up, and crushed ice was added with stirring; more crushed ice was added as the hydrolysis continued. The flask was washed out with some of the cold aqueous material from the hydrolysis. When the hydrolysis was complete, the solids of 5-ethoxy-2-methoxybenzenesulfonyl chloride (2) were filtered and washed with ice water. The yield was about 24 g.

[0098] Preparation of 5-ethoxy-2-methoxy-benzenethioL

[0099] Step iv: Damp 5-ethoxy-2-methoxybenzenesulfonyl chloride (2) from the previous step was added to a mixture of 35 mL 96% sulfuric acid and 560 g crushed ice in a round bottom flask equipped with a condenser, heating mantle, and mechanical stirrer. 31 g Zn powder (325 mesh) was added with stirring. The mixture was heated to reflux with stirring for 1.5 hr. The reaction was cooled, decanted, and filtered, washing the filter cake with CH2CI2. The combined decant and filtrate were extracted withCHjCIa- The CH 2CI2 extract was washed once quickly with 5% NaHCCh, dried, and then the solvent was removed by distillation. The residue was vacuum distilled to yield about 7.8 g of a pale yellow oil (5- ethoxy-2-methoxy-benzenethiol).

[0100] Preparation of (5-ethoxy-2-methoxyphenyl)(propyl)sulfane.

[0101] Step v: 2.5 g of 5-ethoxy-2-methoxy-benzenethiol from the previous step followed by 2.0 mL of 1-iodopropane were added in rapid sequence to 1.2 g of powdered KOH dissolved in 24 mL EtOH at ambient temperature. There was a moderate exotherm and precipitation of KI. The reaction was refluxed for 30 minutes, filtered, the solvent removed, and then short-path vacuum distilled to yield about 3 g of a clear oil.

[0102] Preparation 2-ethoxy-5-methoxy-4-(propylthio)benzaldehyde (3).

[0103] Step vi: A round bottom flask was fitted with a CaCI2drying tube, magnetic stirrer, and heating mantle. 10.3 g of freshly-distilled POCI3 and 14.5 mL / V-methylformanilide were added to the flask and incubated at 50 °C or 20 min. 7.5 g of (5-ethoxy-2-methoxyphenyl)(propyl)sulfane was added and the reaction was heated to 100 °C over a period of 10-15 min. with stirring. After 20 min. of heating, the reaction was poured into 150 mL ice / water with stirring, then stirred for another 30 min until the original thick orange oil had hydrolyzed to a granular floc. The reaction was filtered and the filter cake washed with water. The filter cake was triturated with 80:20 MeOH:H2O, filtered, washed with a little of the MeOH:H2O mixture, then dried to yield 2-ethoxy-5-methoxy-4-(propylthio)benzaldehyde (3). The melting point was 69-71 °C.

[0104] Preparation of (5-ethoxy-2-methoxy-4-(2-nitrovinyl)phenyl)(propyl)sulfane.

[0105] Step vii: 5 g of 2-ethoxy-5-methoxy-4-(propylthio)benzaldehyde (3)from the previous step was mixed with 5 mL nitromethane and 2.5 g of ammonium acetate crystals. The mixture was refluxed for 15 min. and cooled in an ice / NaCI slush bath then washed twice with H2O. 30 mL EtOH was added and heated to boiling with stirring. The reaction was cooled; crystals formed shortly. The product was filtered and dried to yield about 4.5 g of (5-ethoxy-2-methoxy-4-(2-nitrovinyl)phenyl)(propyl)sulfane. The melting point was 106-106.5 °C.

[0106] Preparation of 2-(2-ethoxy-5-methoxy-4-(propylthio)phenyl)ethan-l-amine chloride (2CT7-2EtO chloride; (4)).

[0107] Step viii: The (5-ethoxy-2-methoxy-4-(2-nitrovinyl)phenyl)(propyl)sulfane from the previous step was reduced using a solution of aluminum hydride (AIH3; alane) in tetrahydrofuran (THF). Alane is generated in situ from lithium aluminum hydride (LAH) as follows: a 3 L round bottom reaction flask was equipped with a temperature probe, ice bath, Friedrich condenser, pressure-equalizeddropping funnel, and overhead stirrer. A I M solution of LAH in THF (400 mL, 400 mmol) was charged to the reaction flask and stirred until the solution reached a temperature of 2 °C. One hundred percent sulfuric acid (10.6 mL, 200 mmol), produced by treating 96% H2SO4 with oleum, was added to the cold LAH solution, dropwise with vigorous stirring to avoid charring, over a period of one hour. Hydrogen was evolved and lithium sulfate precipitated to give a clear solution of alane in THF. The (5-ethoxy-2- methoxy-4-(2-nitrovinyl)phenyl)(propyl)sulfane was dissolved in 50 m L THF, then added rapidly to the round bottom flask with stirring while the temperature was maintained in the range of 0-4 °C. After the addition was complete, the reaction was stirred for 30 min. on ice, then the ice bath was removed and replaced with a heating mantle. The reaction was heated to reflux for 3 hr. then returned to the ice bath. Glauber's salt (Na2SO4[H2O]i0; 45 g, 140 mmol) was added in portions with vigorous stirring to quench the reaction while the temperature was maintained below 10 °C. The formed greyish-white solids were removed by suction filtration through Celite 545 and the filter cake was washed with fresh THF. The THF was removed by distillation, then the crude product was distilled using a Kugelrohr to obtain a nearly colorless oil of the amine free base.

[0108] Step ix: The free base was dissolved in isopropyl alcohol then acidified with hydrochloric acid to a slightly acidic pH. Diethyl ether or t-butyl methyl ether was added to initiate crystal formation. The crystals were harvested by suction filtration, washed with fresh ether, and then suctioned dry to yield 2CT7-2EtO chloride (4). The melting point was 187-189 °C.

[0109] Crystallization

[0110] Single crystals suitable for X-ray diffraction studies were grown from the slow evaporation of an acetonitrile solution.

[0111] Single Crystal Characterization

[0112] The single crystal data and structure refinement parameters for the crystalline form 1 structure of 2CT7-2EtO chloride are reported in Table 3, below.Table 3

[0113] FIG. 1 shows the molecular structure of crystalline form 1 of 2CT7-2EtO chloride, showing the atomic labeling.

[0114] FIG. 2 shows the unit cell of crystalline form 1 of 2CT7-2EtO chloride along the c-axis.

[0115] Simulated Powder X-ray Diffraction (PXRD) Pattern

[0116] FIG. 3 shows a simulated X-ray powder diffraction pattern (XRPD) for crystalline form 1 of 2CT7-2EtO chloride generated from its single crystal data. Table 4 lists the angles, °20 ± O.2°20, and d- spacing of the peaks identified in the experimental XRPD pattern of FIG. 3. The entire list of peaks, or a subset thereof, may be sufficient to characterize the cocrystal. For example, the cocrystal may be characterized by at least two peaks selected from the peaks at 11.5, 13.1, and 14.4 °20 + O.2°20 or their corresponding d-spacing as well as by an XRPD pattern substantially similar to FIG. 3.Table 4ReferencesDolomanov, 0. \ / ., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. AppL Cryst. 42, 339-341.Sheldrick, G. M. (2015). Acta Cryst. C71, 3-8.

Claims

The claimed invention is:

1. 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminiurn chloride (2-(2-ethoxy-4- propylsulfanyl-5-methoxyphenyl)ethanaminium chloride).

2. Crystalline 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2-(2-ethoxy- 4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride).

3. Crystalline form 1 of 2-[2-ethoxy-5-methoxy-4-(propylsulfanyl)phenyl]ethan-l-aminium chloride (2- (2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride).

4. Crystalline form 1 of 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to claim 3, characterized by at least one of: a monoclinic crystal system at a temperature of about 300 K; a Pl c space group at a temperature of about 300 K; unit cell dimensions a = 17.660(3) A, b = 8.5544(10) A, c = 11.0406(14) A, a = 90°, 0 = 90.701(5)°, and y = 90°; an X-ray powder diffraction pattern substantially similar to FIG. 3; or an X-ray powder diffraction pattern characterized by at least two peaks selected from 11.5, 13.1, and 14.4 °20 ± 0.2 °29.

5. A composition comprising 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to claim 1 and an excipient.

6. A composition comprising crystalline 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to any one of claims 2-4 and an excipient.

7. A composition comprising 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to claim 1 as a first component and a second component selected from at least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.

8. A composition comprising crystalline 2-(2-ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to any one of claims 2-4 as a first component and a second component selected fromat least one of (a) a serotonergic drug, (b) a purified psilocybin derivative, (c) a purified cannabinoid, (d) a purified terpene, (e) an adrenergic drug, (f) a dopaminergic drug, (g) a monoamine oxidase inhibitor, (h) a purified erinacine, and (i) a purified hericenone.

9. A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 2-(2-ethoxy-4- propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to claim 1.

10. A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 2-(2- ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to any one of claims 2-4.

11. A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to claim 5 or claim 7.

12. A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to claim 6.

13. A method of preventing or treating a psychological disorder comprising the step of: administering to a subject in need thereof a composition according to claim 8.

14. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of 2-(2-ethoxy-4- propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to claim 1.

15. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a therapeutically effective amount of crystalline 2-(2- ethoxy-4-propylsulfanyl-5-methoxyphenyl)ethanaminium chloride according to any one of claims 2-4.

16. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a composition according to claim 5 or claim 7.

17. A method of preventing or treating inflammation and / or pain comprising the step of: administering to a subject in need thereof a composition according to claim 6.

18. A method of preventing or treating inflammation and / or pain comprising the step of:administering to a subject in need thereof a composition according to claim 8.

Images